204 239

Cited 5 times in

Optimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer

DC FieldValueLanguage
dc.contributor.author금기창-
dc.contributor.author김용배-
dc.contributor.author윤홍인-
dc.contributor.author이정심-
dc.contributor.author최진현-
dc.date.accessioned2018-03-26T16:55:25Z-
dc.date.available2018-03-26T16:55:25Z-
dc.date.issued2015-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/156967-
dc.description.abstractPURPOSE: The purpose of this study was to determine optimal extent of prophylactic irradiation of paraaortic lymph nodes (PALN) in patients with uterine cervical cancer who had metastatic pelvic LNs. METHODS AND MATERIALS: We retrospectively evaluated 103 patients with cervical cancer and pelvic lymph node metastasis who were treated with prophylactic semi-extended field radiotherapy (SEFRT) between 1990 and 2012. The semi-extended field included PALN below the second lumbar spine with prescribed doses of 45 to 50 Gy. Survival outcomes were calculated using the Kaplan-Meier method, and acute and late toxicities were scored using the Radiation Therapy Oncology Group and European Organisation for Research and Treatment of Cancer toxicity criteria. RESULTS: The median follow-up after SEFRT was 61 (range 5-296) months. Overall, 28 patients (27.2%) experienced treatment failures, which were classified as local in 8 patients (7.8%), regional in 8 patients (7.8%), and distant in 13 patients (12.6%). Of the regional failures, only two involved PALN failure around the renal artery or the renal hilum area at the upper margin of the semi-extended field. At 5 years, the overall survival was 82%. Grade 3 or higher acute gastrointestinal and genitourinary toxicities occurred in one and two patients, respectively. As a late toxicity, one patient developed grade 3 small bowel obstruction. CONCLUSION: Prophylactic SEFRT provided favorable outcomes with little acute or late gastrointestinal toxicity. For prophylaxis of PALN recurrences, upper part of PALN might not need to be included in patients with uterine cervical cancer and metastatic pelvic LNs.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherPublic Library of Science-
dc.relation.isPartOfPLOS ONE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHFemale-
dc.subject.MESHFollow-Up Studies-
dc.subject.MESHGamma Rays/adverse effects-
dc.subject.MESHGamma Rays/therapeutic use*-
dc.subject.MESHGastrointestinal Diseases/etiology-
dc.subject.MESHHumans-
dc.subject.MESHKaplan-Meier Estimate-
dc.subject.MESHLymph Nodes/pathology*-
dc.subject.MESHLymphatic Metastasis/pathology-
dc.subject.MESHMiddle Aged-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPelvic Neoplasms/mortality-
dc.subject.MESHPelvic Neoplasms/radiotherapy*-
dc.subject.MESHPelvic Neoplasms/secondary-
dc.subject.MESHPositron-Emission Tomography-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTomography, X-Ray Computed-
dc.subject.MESHTreatment Outcome-
dc.subject.MESHUterine Cervical Neoplasms/complications-
dc.subject.MESHUterine Cervical Neoplasms/mortality-
dc.subject.MESHUterine Cervical Neoplasms/pathology*-
dc.titleOptimal Extent of Prophylactic Irradiation of Paraaortic Lymph Nodes in Patients with Uterine Cervical Cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Radiation Oncology-
dc.contributor.googleauthorJinhyun Choi-
dc.contributor.googleauthorHong In Yoon-
dc.contributor.googleauthorJeongshim Lee-
dc.contributor.googleauthorKi Chang Keum-
dc.contributor.googleauthorGwi Eon Kim-
dc.contributor.googleauthorYong Bae Kim-
dc.identifier.doi10.1371/journal.pone.0145158-
dc.contributor.localIdA00272-
dc.contributor.localIdA00744-
dc.contributor.localIdA04777-
dc.contributor.localIdA03112-
dc.contributor.localIdA04697-
dc.relation.journalcodeJ02540-
dc.identifier.eissn1932-6203-
dc.identifier.pmid26659867-
dc.contributor.alternativeNameKeum, Ki Chang-
dc.contributor.alternativeNameKim, Yong Bae-
dc.contributor.alternativeNameYoon, Hong In-
dc.contributor.alternativeNameLee, Jeong Shim-
dc.contributor.alternativeNameChoi, Jinhyun-
dc.contributor.affiliatedAuthorKeum, Ki Chang-
dc.contributor.affiliatedAuthorKim, Yong Bae-
dc.contributor.affiliatedAuthorYoon, Hong In-
dc.contributor.affiliatedAuthorLee, Jeong Shim-
dc.contributor.affiliatedAuthorChoi, Jinhyun-
dc.citation.volume10-
dc.citation.number12-
dc.citation.startPagee0145158-
dc.identifier.bibliographicCitationPLOS ONE, Vol.10(12) : e0145158, 2015-
dc.identifier.rimsid41276-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Radiation Oncology (방사선종양학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.